Cara Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cara Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Cara Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$12.5M, a 55.5% increase year-over-year.
  • Cara Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$95.5M, a 18% increase year-over-year.
  • Cara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$119M, a 38.7% decline from 2022.
  • Cara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$85.5M, a 3.36% increase from 2021.
  • Cara Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$88.4M, a 1152% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$95.5M -$12.5M +$15.6M +55.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$111M -$20M +$11.5M +36.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-14
Q1 2024 -$123M -$30.7M -$4.03M -15.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-14
Q4 2023 -$119M -$32.3M -$2M -6.59% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 -$117M -$28M -$4.85M -20.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$112M -$31.5M -$27.3M -648% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-14
Q1 2023 -$84.4M -$26.7M +$1.08M +3.91% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-14
Q4 2022 -$85.5M -$30.3M +$3.04M +9.12% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 -$88.5M -$23.2M -$22.2M -2188% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$66.4M -$4.21M +$26.5M +86.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 -$92.9M -$27.7M -$4.45M -19.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 -$88.4M -$33.4M -$112M -142% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $23.9M -$1.01M +$15.5M +93.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $8.35M -$30.7M -$5.68M -22.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 $14M -$23.3M +$5.62M +19.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 $8.41M $78.9M +$108M Oct 1, 2020 Dec 31, 2020 10-K 2021-02-25
Q3 2020 -$99.1M -$16.5M +$16.3M +49.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$115M -$25.1M -$2.11M -9.18% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$113M -$28.9M -$6.96M -31.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$106M -$28.6M -$7.96M -38.5% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$98.4M -$32.8M -$13.4M -69.3% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$85M -$23M -$5.77M -33.5% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$79.2M -$22M -$5.19M -31% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$74M -$20.7M -$6.48M -45.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-27
Q3 2018 -$67.5M -$19.4M -$6.96M -55.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-27
Q2 2018 -$60.6M -$17.2M -$7.89M -84.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-27
Q1 2018 -$52.7M -$16.8M +$5.44M +24.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-27
Q4 2017 -$58.1M -$14.2M +$7.79M +35.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$65.9M -$12.4M -$902K -7.82% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-12
Q2 2017 -$65M -$9.3M +$3.78M +28.9% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-12
Q1 2017 -$68.8M -$22.2M -$11.5M -108% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-12
Q4 2016 -$57.3M -$22M -$12.4M -131% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$44.8M -$11.5M -$6.76M -141% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$38.1M -$13.1M -$7.39M -130% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$30.7M -$10.7M -$6M -128% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$24.7M -$9.53M -$5.36M -128% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-10
Q3 2015 -$19.3M -$4.79M +$1.76M +26.9% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-10
Q2 2015 -$21.1M -$5.68M -$2.04M -55.9% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-10
Q1 2015 -$19.1M -$4.69M -$1.31M -38.6% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-10
Q4 2014 -$17.7M -$4.17M -$2.08M -99.3% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-11
Q3 2014 -$15.7M -$6.55M -$1.97M -43.1% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-11
Q2 2014 -$13.7M -$3.65M -$8.98M -168% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-11
Q1 2014 -$4.71M -$3.38M -$751K -28.5% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-11
Q4 2013 -$3.96M -$2.09M Oct 1, 2013 Dec 31, 2013 10-K 2016-03-11
Q3 2013 -$4.58M Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-10
Q2 2013 $5.34M Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-07
Q1 2013 -$2.63M Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.